WIRB-Copernicus Group Supports Accelerated Clinical Trial Agreement
The ACTA was initiated in 2012 by the National Center for Advancing Translational Sciences (NCATS) through its Clinical and Translational Science Awards program in collaboration with representatives from several pharmaceutical companies to facilitate negotiations between institutional research sites and industry sponsors.
WIRB-Copernicus Group (WCG), a provider of regulatory and ethical review services for human research and software solutions, announced that it will encourage members of its Global Research Network (GRN) to accept the Accelerated Clinical Trial Agreement (ACTA) as their default agreement for industry-sponsored, multi-center clinical trials.
The ACTA was initiated in 2012 by the National Center for Advancing Translational Sciences (NCATS) through its Clinical and Translational Science Awards program in collaboration with representatives from several pharmaceutical companies to facilitate negotiations between institutional research sites and industry sponsors. The goal was to create a straightforward and unambiguous document which clearly sets forth the regulatory and contractual obligations of both parties, and presents language which – while perhaps not ideal for either party – is acceptable to both. Adoption and use of the ACTA would expedite the contract process and reduce the time it takes to start up clinical trials.
While the Accelerated Clinical Trial Agreement (ACTA) was initiated in 2012, it took two years to develop, and is just being introduced now. To date, approximately 225 institutions have agreed to the terms of the ACTA. WCG aims to increase that number significantly by promoting ACTA to the 1,200 institutions that belong to its GRN, which is a group comprised of research-intensive hospitals and universities, including one-third of all U.S. academic medical centers, 27 of which are CTSA institutions and have agreed to accept the ACTA without revision.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
